Nektar, Verastem Among Healthcare Additions in Russell Microcap; Assertio, Sangamo Removed
TherapeuticsMD | 10-Q: Quarterly report
Express News | TherapeuticsMD Q1 EPS $(0.07) Up From $(0.24) YoY
Express News | TherapeuticsMD Inc - Continues to Evaluate a Variety of Strategic Alternatives
TherapeuticsMD 1Q Cont Ops Loss/Shr 7c >TXMD
TherapeuticsMD 1Q Cont Ops Loss/Shr 7c >TXMD
Express News | TherapeuticsMD Q1 Operating Expenses USD 1.5 Million
Express News | TherapeuticsMD Announces First Quarter 2024 Financial Results
TherapeuticsMD: Evaluation of Strategic Alternatives Continues >TXMD
TherapeuticsMD: Evaluation of Strategic Alternatives Continues >TXMD
TherapeuticsMD 2023 Cont Ops Loss/Shr 74c >TXMD
TherapeuticsMD 2023 Cont Ops Loss/Shr 74c >TXMD
Press Release: TherapeuticsMD Announces Full Year 2023 Financial Results
TherapeuticsMD Announces Full Year 2023 Financial Results -- Evaluation of strategic alternatives continues BOCA RATON, Fla.--(BUSINESS WIRE)--March 29, 2024-- TherapeuticsMD, Inc. ("TherapeuticsMD
25 Countries With Highest Abortion Rates
A Look Into Healthcare Sector Value Stocks
What Defines a Value Stock?A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indic
TherapeuticsMD(TXMD.US) Officer Sells US$43,683.9 in Common Stocks
$TherapeuticsMD(TXMD.US)$ Officer Walker Marlan D sold 19,050 shares of Common Stocks on Dec 6, 7, 2023 at an average price of $2.2931 for a total value of $43,683.9.Source: Announcement What is state
Stocks to Watch: Getty Images, TherapeuticsMD, Solid Biosciences
By Denny Jacob Getty Images Holdings lowered its 2023 outlook, citing challenges ranging from strikes in Hollywood to a stronger dollar. Shares retreat 5.8% in after-market trading. TherapeuticsMD,
TherapeuticsMD Exploring Strategic Alternatives for Company
TherapeuticsMD Q3 EPS $(0.13) Misses $(0.05) Estimate
TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.05) by 160 percent. This is a 95.27 percent increase over losses of $(2.7
Therapeutics MD GAAP EPS of -$0.13
TherapeuticsMD: Hasn't Set Timetable for Completion of Exploration Process and Doesn't Intend to Disclose Further Developments Unless and Until It Is Determined That Disclosure Is Appropriate or Necessary >TXMD
TherapeuticsMD: Hasn't Set Timetable for Completion of Exploration Process and Doesn't Intend to Disclose Further Developments Unless and Until It Is Determined That Disclosure Is Appropriate or Neces
TherapeuticsMD: Evaluating Strategic Alternatives That May Include an Acquisition, Merger, Other Business Combination, Sale of Assets, or Other Strategic Transactions >TXMD
TherapeuticsMD: Evaluating Strategic Alternatives That May Include an Acquisition, Merger, Other Business Combination, Sale of Assets, or Other Strategic Transactions >TXMD
TherapeuticsMD 3Q Loss/Shr 13c >TXMD
TherapeuticsMD 3Q Loss/Shr 13c >TXMD